HomeCannabisCara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment...

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Published on

STAMFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 24

th

Annual Global Investment Conference on Tuesday, September 13, 2022, at 8:30 a.m. ET.

A webcast of the presentation can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at

www.CaraTherapeutics.com

. An archived webcast recording will be available on the Cara website for approximately 30 days.


About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed the placebo-controlled phase of a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit

www.CaraTherapeutics.com

and follow the company on

Twitter

,

LinkedIn

and

Instagram

.


MEDIA CONTACT:


Annie Spinetta

6 Degrees

973-768-2170


[email protected]


INVESTOR CONTACT:


Iris Francesconi, Ph.D.

Cara Therapeutics

203-406-3700


[email protected]

ti?nf=ODYzOTc3OSM1MTMzNjU5IzIwMDYwMzk= Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference


Primary Logo

Featured image: Megapixl © Lovelyday12

Disclaimer

Latest News

Cannabis companies are thriving as a result of Europe’s call for medical marijuana

A South African manufacturer has sold all of its output for the upcoming year...

Flora Growth Completes Multiple Commercial Cannabis Exports Into New International Markets

Flora (NASDAQ:FLGC) completed dry cannabis flower commercial exports to Switzerland and the Czech...

Global Hemp Fiber Market Rising at an Annual Rate of 6.9%

Las Vegas, NV, Sept. 22, 2022 (GLOBE NEWSWIRE) -- ...

Tilray Brands, Inc. to Announce First Quarter Fiscal 2023 Financial Results on October 7, 2022

NEW YORK and LEAMINGTON, Ontario, Sept. 23, 2022 (GLOBE...

More like this

Skye Bioscience Completes Drug Production for Phase 1 Clinical Study

San Diego, California, Sept. 20, 2022 (GLOBE NEWSWIRE) --...

VIVO Cannabis Announces Agreement to Amend Outstanding Debentures

Toronto, Ontario--(Newsfile Corp. - September 19, 2022) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQX:...

High Tide Closes $19 Million Non-Dilutive Credit Facility with connectFirst Credit Union

High Tide Closes $19 Million Non-Dilutive Credit Facility...